MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT
Minimal Residual Disease, Donor Lymphocyte Infusion, Hematopoietic Stem Cell Transplantation
About this trial
This is an interventional prevention trial for Minimal Residual Disease
Eligibility Criteria
Inclusion Criteria:
- patients with acute leukemia
- receiving allo-HSCT
Exclusion Criteria:
- Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)
- Patients with any conditions not suitable for the trial (investigators' decision)
Sites / Locations
- Department of Hematology,Nanfang Hospital, Southern Medical University
Arms of the Study
Arm 1
Experimental
MRD-directed DLI
For patients with MRD+ and without grade II/>II aGVHD by day +60 post-transplantation, DLI was given once by day +60 and was then administered based on MRD and GVHD status. If patients were MRD negative, DLI was not given again; if patients were MRD positive and without GVHD, DLI was given monthly until GVHD occurred or MRD became negative or for a total of four times. For patients with NR or PR pre-transplantation and with MRD negative by day +60 post-transplantation, DLI was given once by day +90 regardless of MRD, and was then administered when MRD became positive. For patients with CR pre-transplantation and with MRD negative post-transplantation, DLI was not given unless MRD became positive.